Abstracts tagged "Myositis"

Abstract Number: 0641 • ACR Convergence 2025
Safety and efficacy of autologous CD19-CAR T-cell therapy in patients with autoimmune disease – data from the CASTLE Phase I/II basket study
Melanie Hagen¹, Andreas Wirsching¹, Fabian Müller², Soraya Kharboutli³, Christina Bergmann¹, Sebastian Böltz¹, Jule Taubmann⁴, Carlo Tur¹, Laura Bucci¹, Simon Völkl³, Michael Aigner³, Sascha Kretschmann³, Louis Schuster⁴, Koray Tascilar⁴, Silvia Spoerl³, Ingrid Vasova³, Panagiotis Garantziotis¹, Daniel Aletaha⁵, Hans-Peter Kiener⁶, gerlando Natalello⁷, Franco Locatelli⁸, Maria Antonietta D'Agostino⁹, Aline Bozec¹, Linda Hanssens¹⁰, Dirk De Vries¹⁰, Ricardo Grieshaber-Bouyer¹¹, Andreas Mackensen¹² and Georg Schett¹³, ¹Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ²University Hospital of Erlangen, Erlangen, Germany, ³Department of Medicine ⁵ - Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany, ⁴Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany, ⁵Medical University Vienna, Wien, Austria, ⁶Medical University of Vienna, Vienna, Austria, Vienna, Austria, ⁷Division of Rheumatology and Clinical Immunology - Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ⁸IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Italy, ⁹Catholic University of the Sacred Heart, Rome, Rome, Italy, ¹⁰Miltenyi Biomedicine, Bergisch Gladbach, Bergisch Gladbach, Germany, ¹¹University Hospital Erlangen, Erlangen, Germany, ¹²Department of Medicine ⁵ - Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and Uniklinikum Erlangen, Erlangen, Germany, ¹³Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany
Background/Purpose: Engineered T cells expressing a chimeric antigen receptor (CAR) binding CD19 are powerful tools to deplete B-cells, representing an attractive therapy for severe autoimmune…
Abstract Number: 0296 • ACR Convergence 2025
Aggregation of HARS1 and internalized antibodies in muscle biopsies of patients with antisynthetase syndrome and anti-Jo1(HARS) autoantibodies
maria Casal-Dominguez¹, Iago Pinal Fernandez², Katherine Pak², Travis Kinder¹, Jon Musai¹, Ana Matas-Garcia³, Gloria Garrabou⁴, Iban aldecoa⁵, Albert Selva-O´callaghan⁶, José Milisenda⁷ and Andrew Mammen⁸, ¹National Institutes of Health, Bethesda, MD, ²National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ³Muscle Research Unit, Internal Medicine Service, Hospital Clinic, Barcelona, Spain., Barcelona, Spain, ⁴Muscle Research Unit, Internal Medicine Service, Hospital Clinic, Barcelona, Spain., Barcelona, ⁵Pathology, Neurological Tissue Bank. Hospital Clinic of Barcelona-CDB-IDIBAPS/FCRB-University of Barcelona, Barcelona, Spain., Barcelona, ⁶Systemic Autoimmune Disease Section, Vall d'Hebron Institute of Research, Barcelona, Spain, Barcelona, ⁷Hospital Clinic de Barcelona, Barcelona, Spain, ⁸NIH, Bethesda, MD
Background/Purpose: Autoimmune inflammatory myopathies (IMs) comprise a diverse group of diseases that primarily affect the muscles and often involve the lungs, skin, and joints. Among…
Abstract Number: 0026 • ACR Convergence 2025
Spatial Proteomic-based Phenotyping of Muscle Stem Cells and their Niches in Myositis
Bilgesu Safak Tümerdem¹, Yi-Nan Li², Tim Filla³, Rolf Schröder⁴, Anna Brunn⁵, Alexandru Micu⁶, Ayla Nadja Stuetz¹, Laura-Marie Lahu⁶, Aleix Rius Rigau⁷, Christina Bergmann⁸, Alexandru-Emil Matei⁹, Jörg Distler¹⁰ and Andrea-Hermina Györfi¹¹, ¹Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University, Düsseldorf, Nordrhein-Westfalen, Germany, ²University Hospital of Düsseldorf, Düsseldorf, Germany, ³Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University., Düsseldorf, Germany, ⁴Institute of Neuropathology, Friedrich-Alexander University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ⁵Institute of Neuropathology, Heinrich-Heine University, University Hospital of Düsseldorf, Düsseldorf, Germany, ⁶Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University, Düsseldorf, Germany, ⁷Department of Internal Medicine ³, Rheumatology and Clinical Immunology, Friedrich-Alexander-University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen. Deutsches Zentrum Immuntherapie (DZI), Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ⁸Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ⁹Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, and Fraunhofer Cluster of Excellence for Immune Mediated Diseases CIMD, Frankfurt am Main, Germany, Düsseldorf, Germany, ¹⁰University Hospital Duesseldorf and HHU, Duesseldorf, Germany, ¹¹Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University., Düsseldorf, Germany
Background/Purpose: Immune-mediated inflammatory myopathies (IIMs) are a heterogeneous group of diseases characterized by chronic inflammation, damage and impaired regeneration of the skeletal muscle leading to…
Abstract Number: 2078 • ACR Convergence 2025
Neutrophil Extracellular Traps from Patients with Idiopathic Inflammatory Myopathies Induce Interferogenic Responses in Macrophages and Myeloid Dendritic Cells
Yatzil Reyna Juárez¹, Jennifer Tiaré Balderas Miranda², Beatriz Alcalá Carmona³, María José Ostos Prado⁴, karina santana⁵, Diana Gómez-Martín⁶ and Jiram Torres Ruiz⁷, ¹Instituto Politècnico Nacional, Tultitlán de Mariano Escobedo, Mexico State, Mexico, ²Universidad Nacional Autónoma de México, Coyoacán, Federal District, Mexico, ³INCMNSZ, Cdmx, Distrito Federal, Mexico, ⁴Instituto Nacional De Ciencias Médicas Y Nutrición Salvador Zubirán, Mexico City, Distrito Federal, Mexico, ⁵INCMNSZ, Ciudad de México, Federal District, Mexico, ⁶INCMNSZ, Mexico city, Federal District, Mexico, ⁷INCMNSZ, Mexico, Federal District, Mexico
Background/Purpose: Dermatomyositis (DM) and anti-synthetase syndrome (AS) are idiopathic inflammatory myopathies (IIM) with perifascicular pathology involving vasculopathy, macrophages, dendritic cells and an overexpression of interferon-stimulated…
Abstract Number: 2017 • ACR Convergence 2025
Baseline and 2-year Follow-up of Pulmonary Function Among CTD-ILD Subtypes
Ivana Ilic, Anchal Sabharwal, Galina Marder and Sonali Narain, Northwell, Great Neck
Background/Purpose: Interstitial lung disease is a major cause of morbidity and mortality in patients with connective tissue disease (CTD-ILD). Evaluation of ILD severity and progression…
Abstract Number: 1210 • ACR Convergence 2025
Artificial Intelligence-Based Capillaroscopy and Laboratory Biomarkers to Predict Disease Activity in Idiopathic Inflammatory Myopathies: Preliminary Data from the CapIAMI Cohort
Gema María Lledó Ibáñez¹, Jorge Álvarez-Troncoso², Borja del Carmelo Gracia Tello³, Sergio Prieto-Gonzalez⁴, Elena Martínez Robles⁵, Diana Cristina-Varela⁶, Sebastián Molina-Ríos⁷, Luis Sáez Comet⁸, Eiman Soliman⁹, Franklin Uguña¹⁰, Miguel Antonio Mesa¹¹, Miguel Martín Cascón¹², Tânia Santiago¹³, Grace-Jimena Santamaría-Peñaloza¹⁴, Tsvetoslav Georgiev¹⁵, Santiago Bernal-Macias¹⁶, Begoña Marí-Alfonso¹⁷, Jesus Ballano Rodríguez-Solís¹⁸, Sally Patricia Pino Hernández¹⁹, Jacek Olas²⁰, Juan Manuel Mosquera Angarita²¹, Elena García- Guijarro²², Isabel Perales Fraile²³, Mayka Freire Dapena²⁴, Iván Pérez de Pedro²⁵, Luis Adrián Viteri Noël²⁶ and Eduardo Ramos ibáñez²⁷, ¹Hospital Clínic de Barcelona, Barcelona, Spain, ²Hospital Universitario La Paz, Madrid, Madrid, Spain, ³Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain, ⁴Hospital Clinic, Barcelona, Catalonia, Spain, ⁵Hospital Universitario La Paz, Madrid, Spain, ⁶Unidad de Reumatología, Hospital General de Medellín, Medellín, Colombia, Medellín, Colombia, ⁷Hospital Universitario Nacional de Colombia, Bogotá, Colombia, Bogotá, Colombia, ⁸Hospital Universitario Miguel Servet, Zaragoza, Spain, ⁹Alexandria Faculty of Medicine, Alexandria, Egypt, ¹⁰Sociedad Ecuatoriana de Reumatologia, Quito, Ecuador, ¹¹Universidad Pontificia Bolivariana, Medellin, Colombia, ¹²Hospital General Universitario Morales Meseguer, Murcia, Spain, ¹³ULS de Coimbra, Coimbra, Portugal, ¹⁴Hospital Metropolitano, Quito, Ecuador, ¹⁵Hospital St. Marina, Varna, Varna, Bulgaria, ¹⁶Hospital Universitario San Ignacio, Bogotá, Colombia, ¹⁷Hospital Universitario Parc Taulí, Barcelona, Spain, ¹⁸Hospital Universitario del Henares, Alcalá de Henares, Madrid, Spain, ¹⁹Asoreuma, Care for Kids, Bogota, Distrito Capital de Bogota, Colombia, ²⁰MCRIiR, Szpital Specjalistyczny im. J. Dietla w Krakowie, Cracow, Poland, ²¹Hospital Sant Joan de Déu, Barcelona, Spain, ²²Hospital Universitario Infanta Cristina, Madrid, Spain, ²³Hospital Universitario Infanta Sofía, Madrid, Spain, ²⁴Hospital Clínico Universitario de Santiago de Compostela, La Coruña, Spain, ²⁵Hospital Regional Universitario de Málaga, Málaga, Spain, ²⁶Hospital Universitario Ramón y Cajal, Madrid, Spain, ²⁷Capillary.io, Zaragoza, Aragon, Spain
Background/Purpose: Nailfold videocapillaroscopy (NVC) is a valuable non-invasive tool for assessing microvascular damage in autoimmune diseases. However, its application in idiopathic inflammatory myopathies (IIM) remains…
Abstract Number: 0887 • ACR Convergence 2025
Dynamics of cytotoxic and regulatory CD8 T cells underlies outcome in ICI-myotoxicity
Runci Wang¹, Chunyan Xiang², Adrien Procureur³, Julian Sanchez-Dal Cin³, Qing Wang⁴, Xinyue Lian⁵, Michelle Rosenzwajg³, Yves Allenbach⁶, Deepak Rao⁷, Qiong Fu⁸, Nan Shen⁹, Joe-Elie Salem³ and Shuang Ye¹⁰, ¹Department of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China (People's Republic), ²Shanghai Institute of Rheumatology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University (SJTUSM), shanghai, China (People's Republic), ³Sorbonne Université, Paris, France, ⁴Zhongshan Hospital, Shanghai, China (People's Republic), ⁵Renji Hospital, Shanghai, China (People's Republic), ⁶SORBONNE UNIVERSITE, Paris, France, ⁷Brigham and Women's Hospital, Boston, MA, ⁸Renji Hospital, Shanghai, Shanghai, China, ⁹Shanghai Jiang Tong University School of Medicine, Shanghai, China (People's Republic), ¹⁰Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China, Shanghai, Shanghai, China (People's Republic)
Background/Purpose: Immune checkpoint inhibitor (ICI) therapies for cancer can induce immune-related adverse events (irAEs) involving musculoskeletal (MSK) systems. ICI myotoxicity (ICI-M) can present as a…
Abstract Number: 0295 • ACR Convergence 2025
Multidimensional Analysis of Fatigue in Idiopathic Inflammatory Myopathies: Clinical, Psychological, and Sociodemographic Determinants
Manali Sarkar¹, Meera Shah², Vincenzo Venerito³, Vikas Agarwal⁴ and Latika Gupta⁵, ¹Sir H. N. Reliance Foundation Hospital and Research Centre, Mumbai, Maharashtra, India., Mumbai, Maharashtra, India, ²Indraprastha Apollo Hospital, New Delhi, Mumbai, Maharashtra, India, ³Univeristy of Bari "Aldo Moro", Italy, Bari, Bari, Italy, ⁴Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, ⁵School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham; Royal Wolverhampton NHS Trust; Centre for Musculoskeletal Research, School of Biological Sciences, The University of Manchester, Manchester; Francis Crick Institute, London, Birmingham, UK, United Kingdom
Background/Purpose: Fatigue significantly impacts quality of life in idiopathic inflammatory myopathies (IIM) but remains poorly understood. This study aimed to identify the key determinants of…
Abstract Number: 2077 • ACR Convergence 2025
Statin-Associated Immune-Mediated Necrotizing Myopathy in Native Americans
Tam Dinh¹, Evelyn Inga¹, Janelle Francisco¹, Yvonne Waters¹, Krystle Tapia², Maheswari Muruganandam³, N. Suzanne Emil¹, Frank O'Sullivan¹ and Wilmer Sibbitt³, ¹University of New Mexico, Albuquerque, ²University of New Mexico Hospital, Albuquerque, NM, ³University of New Mexico, Albuquerque, NM
Background/Purpose: Immune-mediated necrotizing myopathy (IMNM) is an aggressive subtype of idiopathic inflammatory myopathy (IIM) associated anti-3-hydroxy-3-methylglutaryl coenzyme A reductase (anti-HMGCR) antibodies. Recently there have been…
Abstract Number: 1906 • ACR Convergence 2025
The incidence and mortality of connective tissue diseases in England: a population-level cohort study from 2012 to 2023
Samir Patel¹, Mark Russell¹, Katie Bechman¹, Maryam Adas¹, Zijing Yang¹, Edward Alveyn¹, Chris Wincup², Alexandru Dregan¹, Kate Bramham¹, Sam Norton¹, James Galloway¹ and Patrick Gordon¹, ¹King's College London, London, United Kingdom, ²King's College Hospital, London, United Kingdom
Background/Purpose: The reported incidence and mortality of connective tissue diseases (CTDs) in England has been inconsistent in the literature. Our objective was to describe current…
Abstract Number: 1206 • ACR Convergence 2025
Overexpression of lymphotoxin in autophagy-deficient mice as model for inclusion body myositis
Juliane Bremer¹, Judith Nagel², Jana Zschüntzsch³, Kamil K Zajt¹, Tayfun Palaz¹, Thomas Blank⁴, Aylin Ikis¹, Laura A Fischer³, Anna SM Sensmeyer³, Lara Wiechers³, Josef J Reichelt³, Kai P Hofmann⁵, Monika J Wolf⁶, Corinna Leuchtenberger⁷, Priyanka Tripathi¹, Claudia Einer⁸, Hans Zischka², Ulrike Rothermel⁷, Anna L Eck⁷, Regina Reimann⁹, Veronika Kana⁶, Elisabeth Rushing⁶, Adriano Aguzzi⁶, Marco Prinz⁴, David Liebetanz³, Francesca Odoardi³, Chao-Chung Kuo¹, Joachim Weis¹, Florian Kraft¹, Jens Schmidt¹⁰ and Mathias Heikenwälder⁷, ¹University Hospital RWTH Aachen, Aachen, Germany, ²Technical University of Munich, München, Germany, ³University Medical Center Göttingen, Göttingen, Germany, ⁴University of Freiburg, Freiburg, Germany, ⁵DKFZ Heidelberg, Göttingen, Germany, ⁶University Hospital Zürich, Zürich, Switzerland, ⁷DKFZ Heidelberg, Heidelberg, Germany, ⁸Helmholtz Munich, München, Germany, ⁹University Hospital Zürich, Zürich, Germany, ¹⁰Immanuel University Hospital Rüdersdorf, Brandenburg Medical School, Rüdersdorf bei Berlin, Germany
Background/Purpose: Inclusion body myositis (IBM) is a progressive muscle disorder characterized by inflammation and degeneration with altered proteostasis. To better understand the interrelationship between these…
Abstract Number: 0866 • ACR Convergence 2025
Immunoglobulin from sera of patients with myositis can passively enter cultured human endothelial cells
Travis Kinder¹, maria Casal-Dominguez¹, Iago Pinal Fernandez², Andrew Mammen³ and Sandra Ogbonnaya-Whittlesey⁴, ¹National Institutes of Health, Bethesda, MD, ²National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ³NIH, Bethesda, MD, ⁴NIH/NIAMS, Bethesda, MD
Background/Purpose: Most patients with inflammatory myopathies have autoantibodies to intracellular proteins. We previously showed that immunoglobulin colocalizes with its cognate autoantigen in muscle biopsies from…
Abstract Number: 0294 • ACR Convergence 2025
Clinical relevance of low titer positive myositis-specific autoantibodies and myositis-associated autoantibodies in patients with an underlying malignancy.
Jocelyn Hui Ching Chow¹, Nikola Wilk², Ian Smith³, Ronald A. Booth⁴, Nancy Maltez², Catherine Ivory² and Jodi Warman-Chardon⁵, ¹Department of Medicine, Division of General Internal Medicine, The Ottawa Hospital, University of Ottawa, Ottawa, Canada., Ottawa, ON, Canada, ²Department of Medicine, Division of Rheumatology, The Ottawa Hospital, University of Ottawa, Ottawa, Canada., Ottawa, ON, Canada, ³Department of Medicine, Division of Neurology, The Ottawa Hospital, University of Ottawa, Ottawa, Canada., Ottawa, ON, Canada, ⁴Department of Pathology and Laboratory Medicine, The Ottawa Hospital, University of Ottawa & Eastern Ontario Regional Laboratory Association, Ottawa, ON, Canada., Ottawa, ON, Canada, ⁵Department of Medicine, Division of Neurology, The Ottawa Hospital, University of Ottawa, Ottawa, Canada. Department of Medicine and Cellular and Molecular Medicine, Children’s Hospital of Eastern Ontario, University of Ottawa, Ottawa, ON, Canada., Ottawa, ON, Canada
Background/Purpose: The idiopathic inflammatory myopathies (IIMs) are a heterogeneous group of autoimmune connective tissue diseases that often present with multisystem involvement. Autoantibodies such as myositis-specific…
Abstract Number: 2076 • ACR Convergence 2025
Nutritional Discourse in Online Myositis Communities: A Reddit Analysis of Patient-led Discussions
Latika Gupta¹, Taanya Talreja² and Peter Kerkhof³, ¹School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham; Royal Wolverhampton NHS Trust; Centre for Musculoskeletal Research, School of Biological Sciences, The University of Manchester, Manchester; Francis Crick Institute, London, Birmingham, UK, United Kingdom, ²KEM Hospital, Mumbai, Maharashtra, India, ³Department of Communication Science, Vrije Universiteit Amsterdam, Amsterdam, Netherlands
Background/Purpose: The intersection of nutrition and autoimmune myopathies represents a significant yet understudied domain in rheumatological care. We conducted a meticulous analysis of online myositis…
Abstract Number: 1775 • ACR Convergence 2025
Study Of Type -1 Interferon Gene Signature Markers In Muscle Biopsy Samples Of Patients With IIM
pradeep sosigowda¹, Phani Kumar D¹, Megha Uppin¹ and Liza rajasekhar², ¹NIMS, Hyderabad, Telangana, India, ²Nizam's Institute of Medical Sciences, Hyderabad, Telangana, India
Background/Purpose: Idiopathic inflammatory myopathies (IIMs) are a heterogeneous group of autoimmune diseases primarily affecting skeletal muscle, with potential involvement of other organs. They are classified…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].